Emerging therapies for breast cancer.
Emerging therapies for breast cancer.
复制标题
DOI：
10.1186/s13045-017-0466-3
复制
发表时间：
2017-04-28
影响因子：
28.5
通讯作者：
Fan M
中科院分区：
文献类型：
--
作者：
Hu X;Huang W;Fan M
HER2和CDK4/6无疑是乳腺癌最重要的两个生物学靶点。抗HER2治疗可提高客观反应和无进展存活率/无病存活率以及总体存活率。三种CDK4/6抑制剂持续改善客观反应和无进展生存率；然而，总体生存率数据有待观察。优化化疗和内分泌策略仍然是一个未得到满足的需求。基于检查点抑制物的免疫治疗联合化疗是一个很有前途的领域，尤其是对三阴性乳腺癌。
HER2 and CDK4/6 are undoubted two most important biological targets for breast cancer. Anti-HER2 treatments enhance objective response and progression-free survival/disease-free survival as well as overall survival. Three CDK4/6 inhibitors consistently improve objective response and progression-free survival; however, overall survival data are waited. Optimization of chemotherapy and endocrine strategies remains an unmet need. Check point inhibitor-based immunotherapy combined with chemotherapy is a promising field, especially for triple-negative breast cancer.